Gazette.govt.nzPursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
| Product: | DBL™ Vinblastine |
| Active Ingredient: | Vinblastine sulfate 1mg/mL |
| Dosage Form: | Solution for injection |
| New Zealand Sponsor: | Pfizer New Zealand Limited |
| Manufacturer: | Hospira Australia Pty Limited, Melbourne, Australia |
| Product: | Emtricitabine/Tenofovir disoproxil |
| Active Ingredients: | Emtricitabine 200mg Tenofovir disoproxil succinate 300.6mg equivalent to tenofovir disoproxil 245mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Teva Pharma (New Zealand) Limited |
| Manufacturer: | Remedica Limited, Limassol, Cyprus |
| Product: | Tenofovir disoproxil tablets |
| Active Ingredient: | Tenofovir disoproxil succinate 300.6mg equivalent to tenofovir disoproxil 245mg |
| Dosage Form: | Film coated tablet |
| New Zealand Sponsor: | Teva Pharma (New Zealand) Limited |
| Manufacturer: | Remedica Limited, Limassol, Cyprus |
Dated this 15th day of December 2020.
CHRIS JAMES, Group Manager, Medsafe, Ministry of Health (pursuant to delegation given by the Minister of Health on 11 September 2013).